Additionally, Bufotalin is emerging as a potential anti-tumor agent targeting ferroptosis by promoting the ubiquitination of GPX4 and increasing the intracellular Fe2+ level in NSCLC cells [87]. This evidence concerns the gene GPX4 and non-small cell lung carcinoma.